{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "7a88c4d0",
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import Counter\n",
    "import json\n",
    "import sys\n",
    "import os\n",
    "import re\n",
    "\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "pd.set_option('display.max_colwidth', None)\n",
    "pd.set_option('display.min_rows', 100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "b1dc5d38",
   "metadata": {},
   "outputs": [],
   "source": [
    "pharmgkb_root = '/home/april/projects/opentargets/pharmgkb'\n",
    "clinical_annotations = pd.read_csv(os.path.join(pharmgkb_root, 'clinical', 'clinical_annotations.tsv'), sep='\\t')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "45ec677c",
   "metadata": {},
   "outputs": [],
   "source": [
    "variants = pd.read_csv(os.path.join(pharmgkb_root, 'variants', 'variants.tsv'), sep='\\t')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "fdf1fed4",
   "metadata": {},
   "outputs": [],
   "source": [
    "clinical_ann_alleles = pd.read_csv(os.path.join(pharmgkb_root, 'clinical', 'clinical_ann_alleles.tsv'), sep='\\t')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "c60a3073",
   "metadata": {},
   "outputs": [],
   "source": [
    "ca_with_rs = clinical_annotations[clinical_annotations['Variant/Haplotypes'].str.contains('rs')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "2b8f94fc",
   "metadata": {},
   "outputs": [],
   "source": [
    "calleles_with_rs = clinical_ann_alleles[\n",
    "    clinical_ann_alleles['Clinical Annotation ID'].isin(ca_with_rs['Clinical Annotation ID'])\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "74131976",
   "metadata": {},
   "source": [
    "### Option 1\n",
    "\n",
    "* Use `clinical_ann_alleles.tsv` but only the column with alleles, not the free text.\n",
    "* Use this to get the alleles relevant to the given clinical annotation, then resolve which is ref/alt via... (allele frequencies?  order in the column? something else?)\n",
    "    * Ensembl allele string - assuming first is always ref (?)\n",
    "* Get chrom & pos from NCBI/Ensembl or `variants.tsv`\n",
    "* Won't work for a few rsid records (5013 total > 4416 with rsid > 4350 with exactly 2 alleles)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "74d48b32",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "5013"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(clinical_annotations)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "761c292b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4416"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ca_with_rs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "355cb2dd",
   "metadata": {},
   "outputs": [],
   "source": [
    "results_2_alleles = set()\n",
    "results_more_alleles = set()\n",
    "results_not_snps = set()\n",
    "# Check whether only 2 alleles involved - if so we can determine which is ref (probably)\n",
    "for x in ca_with_rs['Clinical Annotation ID']:\n",
    "    alleles = set()\n",
    "    not_snp = False\n",
    "    for ga in calleles_with_rs[calleles_with_rs['Clinical Annotation ID'] == x]['Genotype/Allele']:\n",
    "        # x chrom\n",
    "        if len(ga) == 1:\n",
    "            alleles.add(ga)\n",
    "            continue\n",
    "        # snp\n",
    "        if len(ga) == 2:\n",
    "            alleles.add(ga[0])\n",
    "            alleles.add(ga[1])\n",
    "            continue\n",
    "        # \"simple\" allele\n",
    "        m = re.match('([ACGT]+|del)/([ACGT]+|del)', ga, re.IGNORECASE)\n",
    "        if not m:\n",
    "            not_snp = True\n",
    "            break\n",
    "        alleles.add(m.group(1))\n",
    "        alleles.add(m.group(2))\n",
    "    if not_snp:\n",
    "        results_not_snps.add(x)\n",
    "    elif len(alleles) <= 2:\n",
    "        results_2_alleles.add(x)\n",
    "    else:\n",
    "        results_more_alleles.add(x)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "c0064598",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4350"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(results_2_alleles)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "450bbb44",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "51"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(results_more_alleles)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "ae9a4f0a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "15"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(results_not_snps)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "3b43e689",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Clinical Annotation ID</th>\n",
       "      <th>Genotype/Allele</th>\n",
       "      <th>Annotation Text</th>\n",
       "      <th>Allele Function</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2303</th>\n",
       "      <td>1183617783</td>\n",
       "      <td>(CCCACCCGA)9/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2304</th>\n",
       "      <td>1183617783</td>\n",
       "      <td>(CCCACCCGA)10/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2305</th>\n",
       "      <td>1183617783</td>\n",
       "      <td>(CCCACCCGA)10/(CCCACCCGA)10</td>\n",
       "      <td>Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2306</th>\n",
       "      <td>1183617783</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2307</th>\n",
       "      <td>1183617783</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)10</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2308</th>\n",
       "      <td>1183617783</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)12</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with antidepressants 1) may have an increased risk of adverse drug reactions after switching treatment for the second time 2) may be more likely to have a lack of a response to treatment as compared to other genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2732</th>\n",
       "      <td>1183615328</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2</td>\n",
       "      <td>Patients with the rs45445694 2R/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) and colorectal cancer may have a decreased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/3R or 3R/3R genotype. Other genetic and clinical factors may also influence risk of asthenia.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2733</th>\n",
       "      <td>1183615328</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 2R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2734</th>\n",
       "      <td>1183615328</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 3R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3134</th>\n",
       "      <td>1183617765</td>\n",
       "      <td>(CCCACCCGA)9/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3135</th>\n",
       "      <td>1183617765</td>\n",
       "      <td>(CCCACCCGA)10/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3136</th>\n",
       "      <td>1183617765</td>\n",
       "      <td>(CCCACCCGA)10/(CCCACCCGA)10</td>\n",
       "      <td>Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3137</th>\n",
       "      <td>1183617765</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3138</th>\n",
       "      <td>1183617765</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)10</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with fluoxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3139</th>\n",
       "      <td>1183617765</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)12</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with fluoxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5249</th>\n",
       "      <td>655385323</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2</td>\n",
       "      <td>Patients with the rs45445694 2R/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) may have increased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R/3R or 3R/3R genotypes. Other genetic and clinical factors may also influence response to methotrexate.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5250</th>\n",
       "      <td>655385323</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 2R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence response to methotrexate.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5251</th>\n",
       "      <td>655385323</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 3R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence response to methotrexate.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5385</th>\n",
       "      <td>981188336</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2</td>\n",
       "      <td>Patients with the rs45445694 2R/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5386</th>\n",
       "      <td>981188336</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 2R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5387</th>\n",
       "      <td>981188336</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 3R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 2R/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5546</th>\n",
       "      <td>981475986</td>\n",
       "      <td>(CA)16/(CA)16</td>\n",
       "      <td>Patients with the (CA)16/(CA)16 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17/(CA)17. Other genetic and clinical factors may also influence gefitinib response.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5547</th>\n",
       "      <td>981475986</td>\n",
       "      <td>(CA)16/(CA)17</td>\n",
       "      <td>Patients with the (CA)16/(CA)17 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17/(CA)17. Other genetic and clinical factors may also influence gefitinib response.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5548</th>\n",
       "      <td>981475986</td>\n",
       "      <td>(CA)17/(CA)17</td>\n",
       "      <td>Patients with the (CA)17/(CA)17 genotype and non-small cell lung cancer may have decreased clinical response when treated with gefitinib as compared to patients with the (CA)16/(CA)16 or (CA)16/(CA)17. Other genetic and clinical factors may also influence gefitinib response.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5920</th>\n",
       "      <td>1451436180</td>\n",
       "      <td>CCCCCCC</td>\n",
       "      <td>Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5921</th>\n",
       "      <td>1451436180</td>\n",
       "      <td>T</td>\n",
       "      <td>Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6029</th>\n",
       "      <td>1451436481</td>\n",
       "      <td>CCCCCCC</td>\n",
       "      <td>Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6030</th>\n",
       "      <td>1451436481</td>\n",
       "      <td>T</td>\n",
       "      <td>Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6034</th>\n",
       "      <td>1451436473</td>\n",
       "      <td>CCCCCCC</td>\n",
       "      <td>Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing hearing loss when treated with dihydrostreptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with dihydrostreptomycin.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6035</th>\n",
       "      <td>1451436473</td>\n",
       "      <td>T</td>\n",
       "      <td>Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with dihydrostreptomycin as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with dihydrostreptomycin.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9074</th>\n",
       "      <td>1444607379</td>\n",
       "      <td>(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)9 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9075</th>\n",
       "      <td>1444607379</td>\n",
       "      <td>(CCCACCCGA)10</td>\n",
       "      <td>Patients with the (CCCACCCGA)10 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9076</th>\n",
       "      <td>1444607379</td>\n",
       "      <td>CCCACCCGA)12/(CCCACCCGA)12</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with sertraline may have a better response to treatment as compared to other genotypes. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9331</th>\n",
       "      <td>1183697617</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R/2R genotype and blood cancers may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/3R or 3R/3R genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9332</th>\n",
       "      <td>1183697617</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R/3R genotype and blood cancers may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9333</th>\n",
       "      <td>1183697617</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R/3R genotype and blood cancers may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13022</th>\n",
       "      <td>1447991729</td>\n",
       "      <td>(CCCACCCGA)9/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13023</th>\n",
       "      <td>1447991729</td>\n",
       "      <td>(CCCACCCGA)10/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13024</th>\n",
       "      <td>1447991729</td>\n",
       "      <td>(CCCACCCGA)10/(CCCACCCGA)10</td>\n",
       "      <td>Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13025</th>\n",
       "      <td>1447991729</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)9</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13026</th>\n",
       "      <td>1447991729</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)10</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13027</th>\n",
       "      <td>1447991729</td>\n",
       "      <td>(CCCACCCGA)12/(CCCACCCGA)12</td>\n",
       "      <td>Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with paroxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13915</th>\n",
       "      <td>1451114600</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R/2R genotype may have an increased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13916</th>\n",
       "      <td>1451114600</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R/3R genotype may have an increased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with the 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13917</th>\n",
       "      <td>1451114600</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R/3R genotype may have a decreased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R/2R or 2R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13918</th>\n",
       "      <td>1451114960</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R/3R or 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13919</th>\n",
       "      <td>1451114960</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R/3R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13920</th>\n",
       "      <td>1451114960</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R/2R or 2R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15442</th>\n",
       "      <td>1451553326</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2</td>\n",
       "      <td>The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 (2R/2R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15443</th>\n",
       "      <td>1451553326</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (2R/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15444</th>\n",
       "      <td>1451553326</td>\n",
       "      <td>(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3</td>\n",
       "      <td>The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (3R/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Clinical Annotation ID  \\\n",
       "2303               1183617783   \n",
       "2304               1183617783   \n",
       "2305               1183617783   \n",
       "2306               1183617783   \n",
       "2307               1183617783   \n",
       "2308               1183617783   \n",
       "2732               1183615328   \n",
       "2733               1183615328   \n",
       "2734               1183615328   \n",
       "3134               1183617765   \n",
       "3135               1183617765   \n",
       "3136               1183617765   \n",
       "3137               1183617765   \n",
       "3138               1183617765   \n",
       "3139               1183617765   \n",
       "5249                655385323   \n",
       "5250                655385323   \n",
       "5251                655385323   \n",
       "5385                981188336   \n",
       "5386                981188336   \n",
       "5387                981188336   \n",
       "5546                981475986   \n",
       "5547                981475986   \n",
       "5548                981475986   \n",
       "5920               1451436180   \n",
       "5921               1451436180   \n",
       "6029               1451436481   \n",
       "6030               1451436481   \n",
       "6034               1451436473   \n",
       "6035               1451436473   \n",
       "9074               1444607379   \n",
       "9075               1444607379   \n",
       "9076               1444607379   \n",
       "9331               1183697617   \n",
       "9332               1183697617   \n",
       "9333               1183697617   \n",
       "13022              1447991729   \n",
       "13023              1447991729   \n",
       "13024              1447991729   \n",
       "13025              1447991729   \n",
       "13026              1447991729   \n",
       "13027              1447991729   \n",
       "13915              1451114600   \n",
       "13916              1451114600   \n",
       "13917              1451114600   \n",
       "13918              1451114960   \n",
       "13919              1451114960   \n",
       "13920              1451114960   \n",
       "15442              1451553326   \n",
       "15443              1451553326   \n",
       "15444              1451553326   \n",
       "\n",
       "                                                       Genotype/Allele  \\\n",
       "2303                                         (CCCACCCGA)9/(CCCACCCGA)9   \n",
       "2304                                        (CCCACCCGA)10/(CCCACCCGA)9   \n",
       "2305                                       (CCCACCCGA)10/(CCCACCCGA)10   \n",
       "2306                                        (CCCACCCGA)12/(CCCACCCGA)9   \n",
       "2307                                       (CCCACCCGA)12/(CCCACCCGA)10   \n",
       "2308                                       (CCCACCCGA)12/(CCCACCCGA)12   \n",
       "2732   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2   \n",
       "2733   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "2734   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "3134                                         (CCCACCCGA)9/(CCCACCCGA)9   \n",
       "3135                                        (CCCACCCGA)10/(CCCACCCGA)9   \n",
       "3136                                       (CCCACCCGA)10/(CCCACCCGA)10   \n",
       "3137                                        (CCCACCCGA)12/(CCCACCCGA)9   \n",
       "3138                                       (CCCACCCGA)12/(CCCACCCGA)10   \n",
       "3139                                       (CCCACCCGA)12/(CCCACCCGA)12   \n",
       "5249   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2   \n",
       "5250   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "5251   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "5385   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2   \n",
       "5386   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "5387   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "5546                                                     (CA)16/(CA)16   \n",
       "5547                                                     (CA)16/(CA)17   \n",
       "5548                                                     (CA)17/(CA)17   \n",
       "5920                                                           CCCCCCC   \n",
       "5921                                                                 T   \n",
       "6029                                                           CCCCCCC   \n",
       "6030                                                                 T   \n",
       "6034                                                           CCCCCCC   \n",
       "6035                                                                 T   \n",
       "9074                                                      (CCCACCCGA)9   \n",
       "9075                                                     (CCCACCCGA)10   \n",
       "9076                                        CCCACCCGA)12/(CCCACCCGA)12   \n",
       "9331   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2   \n",
       "9332   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "9333   (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "13022                                        (CCCACCCGA)9/(CCCACCCGA)9   \n",
       "13023                                       (CCCACCCGA)10/(CCCACCCGA)9   \n",
       "13024                                      (CCCACCCGA)10/(CCCACCCGA)10   \n",
       "13025                                       (CCCACCCGA)12/(CCCACCCGA)9   \n",
       "13026                                      (CCCACCCGA)12/(CCCACCCGA)10   \n",
       "13027                                      (CCCACCCGA)12/(CCCACCCGA)12   \n",
       "13915  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2   \n",
       "13916  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "13917  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "13918  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2   \n",
       "13919  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "13920  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "15442  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2   \n",
       "15443  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "15444  (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Annotation Text  \\\n",
       "2303                                                                                                                               Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "2304                                                                                                                              Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "2305                                                                                                                             Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "2306                                                                                                                              Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "2307                                                                                                                             Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "2308                                                                                                                                                                 Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with antidepressants 1) may have an increased risk of adverse drug reactions after switching treatment for the second time 2) may be more likely to have a lack of a response to treatment as compared to other genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "2732                                                                                                                                                                                                                  Patients with the rs45445694 2R/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) and colorectal cancer may have a decreased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/3R or 3R/3R genotype. Other genetic and clinical factors may also influence risk of asthenia.   \n",
       "2733                                                                                                                                                                                                                          Patients with the rs45445694 2R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.   \n",
       "2734                                                                                                                                                                                                                          Patients with the rs45445694 3R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.   \n",
       "3134                                                                                                                                                          Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "3135                                                                                                                                                         Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "3136                                                                                                                                                        Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "3137                                                                                                                                                         Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "3138                                                                                                                                                           Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with fluoxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "3139                                                                                                                                                                                                  Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with fluoxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "5249                                                                                                                                                                                                                                  Patients with the rs45445694 2R/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) may have increased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R/3R or 3R/3R genotypes. Other genetic and clinical factors may also influence response to methotrexate.   \n",
       "5250                                                                                                                                                                                                                                            Patients with the rs45445694 2R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence response to methotrexate.   \n",
       "5251                                                                                                                                                                                                                                            Patients with the rs45445694 3R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence response to methotrexate.   \n",
       "5385                                                                                                                                                                            Patients with the rs45445694 2R/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.   \n",
       "5386                                                                                                                                                                            Patients with the rs45445694 2R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.   \n",
       "5387                                                                                                                                                                            Patients with the rs45445694 3R/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 2R/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.   \n",
       "5546                                                                                                                                                                                                                                                                                                        Patients with the (CA)16/(CA)16 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17/(CA)17. Other genetic and clinical factors may also influence gefitinib response.   \n",
       "5547                                                                                                                                                                                                                                                                                                        Patients with the (CA)16/(CA)17 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17/(CA)17. Other genetic and clinical factors may also influence gefitinib response.   \n",
       "5548                                                                                                                                                                                                                                                                                       Patients with the (CA)17/(CA)17 genotype and non-small cell lung cancer may have decreased clinical response when treated with gefitinib as compared to patients with the (CA)16/(CA)16 or (CA)16/(CA)17. Other genetic and clinical factors may also influence gefitinib response.   \n",
       "5920                                                                                                                                      Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.   \n",
       "5921                                                                                                                     Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.   \n",
       "6029                                                                     Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.   \n",
       "6030                                                    Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.   \n",
       "6034                                                                                                        Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing hearing loss when treated with dihydrostreptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with dihydrostreptomycin.   \n",
       "6035                                                                                       Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with dihydrostreptomycin as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with dihydrostreptomycin.   \n",
       "9074                                                                                       Patients with the (CCCACCCGA)9 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "9075                                                                                      Patients with the (CCCACCCGA)10 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "9076                                                                                                           Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with sertraline may have a better response to treatment as compared to other genotypes. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "9331                                                                                                                                                                    Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R/2R genotype and blood cancers may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/3R or 3R/3R genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.   \n",
       "9332                                                                                                                                                                               Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R/3R genotype and blood cancers may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.   \n",
       "9333                                                                                                                                                                               Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R/3R genotype and blood cancers may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.   \n",
       "13022                                                                                                                                                         Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "13023                                                                                                                                                        Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "13024                                                                                                                                                       Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "13025                                                                                                                                                        Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "13026                                                                                                                                                          Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "13027                                                                                                                                                                                                 Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with paroxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.   \n",
       "13915                                                                                                                                                                          Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R/2R genotype may have an increased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.   \n",
       "13916                                                                                                                                                                      Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R/3R genotype may have an increased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with the 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.   \n",
       "13917                                                                                                                                                              Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R/3R genotype may have a decreased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R/2R or 2R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.   \n",
       "13918                                                                                                                                                   Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R/3R or 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.   \n",
       "13919                                                                                                                                                            Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R/3R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 3R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.   \n",
       "13920                                                                                                                                                    Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R/2R or 2R/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.   \n",
       "15442  The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 (2R/2R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.   \n",
       "15443  The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (2R/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.   \n",
       "15444  The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (3R/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.   \n",
       "\n",
       "      Allele Function  \n",
       "2303              NaN  \n",
       "2304              NaN  \n",
       "2305              NaN  \n",
       "2306              NaN  \n",
       "2307              NaN  \n",
       "2308              NaN  \n",
       "2732              NaN  \n",
       "2733              NaN  \n",
       "2734              NaN  \n",
       "3134              NaN  \n",
       "3135              NaN  \n",
       "3136              NaN  \n",
       "3137              NaN  \n",
       "3138              NaN  \n",
       "3139              NaN  \n",
       "5249              NaN  \n",
       "5250              NaN  \n",
       "5251              NaN  \n",
       "5385              NaN  \n",
       "5386              NaN  \n",
       "5387              NaN  \n",
       "5546              NaN  \n",
       "5547              NaN  \n",
       "5548              NaN  \n",
       "5920              NaN  \n",
       "5921              NaN  \n",
       "6029              NaN  \n",
       "6030              NaN  \n",
       "6034              NaN  \n",
       "6035              NaN  \n",
       "9074              NaN  \n",
       "9075              NaN  \n",
       "9076              NaN  \n",
       "9331              NaN  \n",
       "9332              NaN  \n",
       "9333              NaN  \n",
       "13022             NaN  \n",
       "13023             NaN  \n",
       "13024             NaN  \n",
       "13025             NaN  \n",
       "13026             NaN  \n",
       "13027             NaN  \n",
       "13915             NaN  \n",
       "13916             NaN  \n",
       "13917             NaN  \n",
       "13918             NaN  \n",
       "13919             NaN  \n",
       "13920             NaN  \n",
       "15442             NaN  \n",
       "15443             NaN  \n",
       "15444             NaN  "
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "calleles_with_rs[calleles_with_rs['Clinical Annotation ID'].isin(results_not_snps)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "0d6f8b9b",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Clinical Annotation ID</th>\n",
       "      <th>Genotype/Allele</th>\n",
       "      <th>Annotation Text</th>\n",
       "      <th>Allele Function</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>160</th>\n",
       "      <td>1450375701</td>\n",
       "      <td>AA</td>\n",
       "      <td>Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>161</th>\n",
       "      <td>1450375701</td>\n",
       "      <td>AC</td>\n",
       "      <td>Patients with the AC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>162</th>\n",
       "      <td>1450375701</td>\n",
       "      <td>AT</td>\n",
       "      <td>Patients with the AT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>163</th>\n",
       "      <td>1450375701</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>164</th>\n",
       "      <td>1450375701</td>\n",
       "      <td>CT</td>\n",
       "      <td>Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>165</th>\n",
       "      <td>1450375701</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>757</th>\n",
       "      <td>1449004745</td>\n",
       "      <td>AA</td>\n",
       "      <td>Patients with Mesothelioma and the AA genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>758</th>\n",
       "      <td>1449004745</td>\n",
       "      <td>AG</td>\n",
       "      <td>Patients with Mesothelioma and the AC genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>759</th>\n",
       "      <td>1449004745</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with Mesothelioma and the CC genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the AA and AC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>799</th>\n",
       "      <td>1449645498</td>\n",
       "      <td>AA</td>\n",
       "      <td>Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>800</th>\n",
       "      <td>1449645498</td>\n",
       "      <td>AC</td>\n",
       "      <td>Patients with the AC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>801</th>\n",
       "      <td>1449645498</td>\n",
       "      <td>AT</td>\n",
       "      <td>There is currently no published evidence to suggest how the AT genotype may affect acetaminophen sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>802</th>\n",
       "      <td>1449645498</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes, but a decreased rate of acetaminophen sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>803</th>\n",
       "      <td>1449645498</td>\n",
       "      <td>CT</td>\n",
       "      <td>Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>804</th>\n",
       "      <td>1449645498</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>808</th>\n",
       "      <td>1449645513</td>\n",
       "      <td>AA</td>\n",
       "      <td>Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>809</th>\n",
       "      <td>1449645513</td>\n",
       "      <td>AC</td>\n",
       "      <td>Patients with the AC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>810</th>\n",
       "      <td>1449645513</td>\n",
       "      <td>AT</td>\n",
       "      <td>There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>811</th>\n",
       "      <td>1449645513</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes, but a decreased rate of tapentadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>812</th>\n",
       "      <td>1449645513</td>\n",
       "      <td>CT</td>\n",
       "      <td>Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>813</th>\n",
       "      <td>1449645513</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>814</th>\n",
       "      <td>1449645522</td>\n",
       "      <td>AA</td>\n",
       "      <td>Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>815</th>\n",
       "      <td>1449645522</td>\n",
       "      <td>AC</td>\n",
       "      <td>Patients with the AC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>816</th>\n",
       "      <td>1449645522</td>\n",
       "      <td>AT</td>\n",
       "      <td>There is currently no published evidence to suggest how the AT genotype may affect O-desmethyl-tramadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>817</th>\n",
       "      <td>1449645522</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CT or TT genotypes, but a decreased rate of O-desmethyl-tramadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>818</th>\n",
       "      <td>1449645522</td>\n",
       "      <td>CT</td>\n",
       "      <td>Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>819</th>\n",
       "      <td>1449645522</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1186</th>\n",
       "      <td>1152661500</td>\n",
       "      <td>AA</td>\n",
       "      <td>Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1187</th>\n",
       "      <td>1152661500</td>\n",
       "      <td>AC</td>\n",
       "      <td>Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1188</th>\n",
       "      <td>1152661500</td>\n",
       "      <td>AT</td>\n",
       "      <td>Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14087</th>\n",
       "      <td>1449167512</td>\n",
       "      <td>AA</td>\n",
       "      <td>Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14088</th>\n",
       "      <td>1449167512</td>\n",
       "      <td>AG</td>\n",
       "      <td>Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14089</th>\n",
       "      <td>1449167512</td>\n",
       "      <td>AT</td>\n",
       "      <td>Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14090</th>\n",
       "      <td>1449167512</td>\n",
       "      <td>GG</td>\n",
       "      <td>Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14091</th>\n",
       "      <td>1449167512</td>\n",
       "      <td>GT</td>\n",
       "      <td>Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14092</th>\n",
       "      <td>1449167512</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14093</th>\n",
       "      <td>1449167529</td>\n",
       "      <td>AA</td>\n",
       "      <td>Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14094</th>\n",
       "      <td>1449167529</td>\n",
       "      <td>AC</td>\n",
       "      <td>Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14095</th>\n",
       "      <td>1449167529</td>\n",
       "      <td>AT</td>\n",
       "      <td>Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14096</th>\n",
       "      <td>1449167529</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14097</th>\n",
       "      <td>1449167529</td>\n",
       "      <td>CT</td>\n",
       "      <td>Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14098</th>\n",
       "      <td>1449167529</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14351</th>\n",
       "      <td>1450811035</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with the CC genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14352</th>\n",
       "      <td>1450811035</td>\n",
       "      <td>CG</td>\n",
       "      <td>Patients with the CG genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14353</th>\n",
       "      <td>1450811035</td>\n",
       "      <td>CT</td>\n",
       "      <td>Patients with the CT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14354</th>\n",
       "      <td>1450811035</td>\n",
       "      <td>GG</td>\n",
       "      <td>Patients with the GG genotype may experience increased inhibition of KCNH2 by disopyramide as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14355</th>\n",
       "      <td>1450811035</td>\n",
       "      <td>GT</td>\n",
       "      <td>Patients with the GT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14356</th>\n",
       "      <td>1450811035</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14357</th>\n",
       "      <td>1450811044</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with the CC genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14358</th>\n",
       "      <td>1450811044</td>\n",
       "      <td>CG</td>\n",
       "      <td>Patients with the CG genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14359</th>\n",
       "      <td>1450811044</td>\n",
       "      <td>CT</td>\n",
       "      <td>Patients with the CT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14360</th>\n",
       "      <td>1450811044</td>\n",
       "      <td>GG</td>\n",
       "      <td>Patients with the GG genotype may experience increased inhibition of KCNH2 by quinidine as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14361</th>\n",
       "      <td>1450811044</td>\n",
       "      <td>GT</td>\n",
       "      <td>Patients with the GT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14362</th>\n",
       "      <td>1450811044</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14677</th>\n",
       "      <td>1450934668</td>\n",
       "      <td>CC</td>\n",
       "      <td>Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14678</th>\n",
       "      <td>1450934668</td>\n",
       "      <td>CG</td>\n",
       "      <td>Patients with the CG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14679</th>\n",
       "      <td>1450934668</td>\n",
       "      <td>CT</td>\n",
       "      <td>Patients with the CT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14680</th>\n",
       "      <td>1450934668</td>\n",
       "      <td>GG</td>\n",
       "      <td>Patients with the GG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14681</th>\n",
       "      <td>1450934668</td>\n",
       "      <td>GT</td>\n",
       "      <td>Patients with the GT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14682</th>\n",
       "      <td>1450934668</td>\n",
       "      <td>TT</td>\n",
       "      <td>Patients with the TT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>272 rows  4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       Clinical Annotation ID Genotype/Allele  \\\n",
       "160                1450375701              AA   \n",
       "161                1450375701              AC   \n",
       "162                1450375701              AT   \n",
       "163                1450375701              CC   \n",
       "164                1450375701              CT   \n",
       "165                1450375701              TT   \n",
       "757                1449004745              AA   \n",
       "758                1449004745              AG   \n",
       "759                1449004745              CC   \n",
       "799                1449645498              AA   \n",
       "800                1449645498              AC   \n",
       "801                1449645498              AT   \n",
       "802                1449645498              CC   \n",
       "803                1449645498              CT   \n",
       "804                1449645498              TT   \n",
       "808                1449645513              AA   \n",
       "809                1449645513              AC   \n",
       "810                1449645513              AT   \n",
       "811                1449645513              CC   \n",
       "812                1449645513              CT   \n",
       "813                1449645513              TT   \n",
       "814                1449645522              AA   \n",
       "815                1449645522              AC   \n",
       "816                1449645522              AT   \n",
       "817                1449645522              CC   \n",
       "818                1449645522              CT   \n",
       "819                1449645522              TT   \n",
       "1186               1152661500              AA   \n",
       "1187               1152661500              AC   \n",
       "1188               1152661500              AT   \n",
       "...                       ...             ...   \n",
       "14087              1449167512              AA   \n",
       "14088              1449167512              AG   \n",
       "14089              1449167512              AT   \n",
       "14090              1449167512              GG   \n",
       "14091              1449167512              GT   \n",
       "14092              1449167512              TT   \n",
       "14093              1449167529              AA   \n",
       "14094              1449167529              AC   \n",
       "14095              1449167529              AT   \n",
       "14096              1449167529              CC   \n",
       "14097              1449167529              CT   \n",
       "14098              1449167529              TT   \n",
       "14351              1450811035              CC   \n",
       "14352              1450811035              CG   \n",
       "14353              1450811035              CT   \n",
       "14354              1450811035              GG   \n",
       "14355              1450811035              GT   \n",
       "14356              1450811035              TT   \n",
       "14357              1450811044              CC   \n",
       "14358              1450811044              CG   \n",
       "14359              1450811044              CT   \n",
       "14360              1450811044              GG   \n",
       "14361              1450811044              GT   \n",
       "14362              1450811044              TT   \n",
       "14677              1450934668              CC   \n",
       "14678              1450934668              CG   \n",
       "14679              1450934668              CT   \n",
       "14680              1450934668              GG   \n",
       "14681              1450934668              GT   \n",
       "14682              1450934668              TT   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                     Annotation Text  \\\n",
       "160                                                                                                                                      Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.   \n",
       "161                                                                                                                                     Patients with the AC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.   \n",
       "162                                                                                                                                      Patients with the AT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.   \n",
       "163                                                                                                                                     Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.   \n",
       "164                                                                                                                                     Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.   \n",
       "165                                                                                                                                      Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.   \n",
       "757                                         Patients with Mesothelioma and the AA genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.   \n",
       "758                                         Patients with Mesothelioma and the AC genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.   \n",
       "759                               Patients with Mesothelioma and the CC genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the AA and AC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.   \n",
       "799                                                                                                                         Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.   \n",
       "800                                                                                                                         Patients with the AC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.   \n",
       "801                                                                                                                                                                                                                                          There is currently no published evidence to suggest how the AT genotype may affect acetaminophen sulfation in patients.   \n",
       "802                         Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes, but a decreased rate of acetaminophen sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.   \n",
       "803                                                                                                                           Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.   \n",
       "804                                                                                                                           Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.   \n",
       "808                                                                                                                               Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.   \n",
       "809                                                                                                                               Patients with the AC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.   \n",
       "810                                                                                                                                                                                                                                             There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.   \n",
       "811                                  Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes, but a decreased rate of tapentadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.   \n",
       "812                                                                                                                                 Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.   \n",
       "813                                                                                                                                 Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.   \n",
       "814                                                                                Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.   \n",
       "815                                                                                                           Patients with the AC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.   \n",
       "816                                                                                                                                                                                                                                   There is currently no published evidence to suggest how the AT genotype may affect O-desmethyl-tramadol sulfation in patients.   \n",
       "817    Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CT or TT genotypes, but a decreased rate of O-desmethyl-tramadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.   \n",
       "818                                                                                                             Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.   \n",
       "819                                                                                                             Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.   \n",
       "1186                                                       Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.   \n",
       "1187                                              Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.   \n",
       "1188                                                               Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.   \n",
       "...                                                                                                                                                                                                                                                                                                                                                              ...   \n",
       "14087                                                                     Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14088                                                             Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14089                                                                     Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14090                                                             Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14091                                                             Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14092                                                                     Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14093                                                                     Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14094                                                             Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14095                                                                     Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14096                                                             Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14097                                                             Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14098                                                                     Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate   \n",
       "14351                                          Patients with the CC genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.   \n",
       "14352                                          Patients with the CG genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.   \n",
       "14353                                          Patients with the CT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.   \n",
       "14354                                                                                                                Patients with the GG genotype may experience increased inhibition of KCNH2 by disopyramide as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.   \n",
       "14355                                          Patients with the GT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.   \n",
       "14356                                          Patients with the TT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.   \n",
       "14357                                                                                                                                          Patients with the CC genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.   \n",
       "14358                                                                                                                                          Patients with the CG genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.   \n",
       "14359                                                                                                                                          Patients with the CT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.   \n",
       "14360                                                                                                                      Patients with the GG genotype may experience increased inhibition of KCNH2 by quinidine as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.   \n",
       "14361                                                                                                                                          Patients with the GT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.   \n",
       "14362                                                                                                                                          Patients with the TT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.   \n",
       "14677                                                                                                                                     Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.   \n",
       "14678                                                                                                                                                                             Patients with the CG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.   \n",
       "14679                                                                                                                                     Patients with the CT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.   \n",
       "14680                                                                                                                                                                             Patients with the GG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.   \n",
       "14681                                                                                                                                                                             Patients with the GT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.   \n",
       "14682                                                                                                                                     Patients with the TT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.   \n",
       "\n",
       "      Allele Function  \n",
       "160               NaN  \n",
       "161               NaN  \n",
       "162               NaN  \n",
       "163               NaN  \n",
       "164               NaN  \n",
       "165               NaN  \n",
       "757               NaN  \n",
       "758               NaN  \n",
       "759               NaN  \n",
       "799               NaN  \n",
       "800               NaN  \n",
       "801               NaN  \n",
       "802               NaN  \n",
       "803               NaN  \n",
       "804               NaN  \n",
       "808               NaN  \n",
       "809               NaN  \n",
       "810               NaN  \n",
       "811               NaN  \n",
       "812               NaN  \n",
       "813               NaN  \n",
       "814               NaN  \n",
       "815               NaN  \n",
       "816               NaN  \n",
       "817               NaN  \n",
       "818               NaN  \n",
       "819               NaN  \n",
       "1186              NaN  \n",
       "1187              NaN  \n",
       "1188              NaN  \n",
       "...               ...  \n",
       "14087             NaN  \n",
       "14088             NaN  \n",
       "14089             NaN  \n",
       "14090             NaN  \n",
       "14091             NaN  \n",
       "14092             NaN  \n",
       "14093             NaN  \n",
       "14094             NaN  \n",
       "14095             NaN  \n",
       "14096             NaN  \n",
       "14097             NaN  \n",
       "14098             NaN  \n",
       "14351             NaN  \n",
       "14352             NaN  \n",
       "14353             NaN  \n",
       "14354             NaN  \n",
       "14355             NaN  \n",
       "14356             NaN  \n",
       "14357             NaN  \n",
       "14358             NaN  \n",
       "14359             NaN  \n",
       "14360             NaN  \n",
       "14361             NaN  \n",
       "14362             NaN  \n",
       "14677             NaN  \n",
       "14678             NaN  \n",
       "14679             NaN  \n",
       "14680             NaN  \n",
       "14681             NaN  \n",
       "14682             NaN  \n",
       "\n",
       "[272 rows x 4 columns]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "calleles_with_rs[calleles_with_rs['Clinical Annotation ID'].isin(results_more_alleles)]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a3d15041",
   "metadata": {},
   "source": [
    "Examples of how to get from clinical annotation to `chr_pos_ref_alt`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "d28e86dd",
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "62c29308",
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_coordinates_for_rs(rsid):\n",
    "    # can do this in bulk too probably\n",
    "    if not rsid.startswith('rs'):\n",
    "        rsid = f'rs{rsid}'\n",
    "    ensembl_url = f'https://rest.ensembl.org/variation/human/{rsid}?content-type=application/json'\n",
    "    resp = requests.get(ensembl_url)\n",
    "    data = resp.json()\n",
    "    if 'mappings' in data:\n",
    "        for m in data['mappings']:\n",
    "            if m['assembly_name'] == 'GRCh38':\n",
    "                break\n",
    "        chrom = m['seq_region_name']\n",
    "        pos = m['start']\n",
    "        alleles = m['allele_string'].split('/')\n",
    "        ref = alleles[0]\n",
    "        alts = alleles[1:]\n",
    "        return chrom, pos, ref, alts\n",
    "    return None, None, None, None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "f3ca0b84",
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_coordinates_for_clinical_annotation(caid):\n",
    "    rs = ca_with_rs[ca_with_rs['Clinical Annotation ID'] == caid]['Variant/Haplotypes'].iloc[0]\n",
    "    chrom, pos, ref, alts = get_coordinates_for_rs(rs)\n",
    "    if not chrom or not pos or not ref or not alts:\n",
    "        return None\n",
    "    if len(alts) == 1:\n",
    "        return f'{chrom}_{pos}_{ref}_{alts[0]}'\n",
    "    # If multiple alts, check what is referred to in the clinical alleles table\n",
    "    alleles = set()\n",
    "    for ga in calleles_with_rs[calleles_with_rs['Clinical Annotation ID'] == caid]['Genotype/Allele']:\n",
    "        # x chrom\n",
    "        if len(ga) == 1:\n",
    "            alleles.add(ga)\n",
    "            continue\n",
    "        # snp\n",
    "        if len(ga) == 2:\n",
    "            alleles.add(ga[0])\n",
    "            alleles.add(ga[1])\n",
    "            continue\n",
    "        # \"simple\" allele\n",
    "        m = re.match('([ACGT]+|del)/([ACGT]+|del)', ga, re.IGNORECASE)\n",
    "        if not m:\n",
    "            break\n",
    "        alleles.add(m.group(1))\n",
    "        alleles.add(m.group(2))\n",
    "    for a in alleles:\n",
    "        if a in alts:\n",
    "            return f'{chrom}_{pos}_{ref}_{a}'\n",
    "    return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "88fbde1c",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://www.pharmgkb.org/clinicalAnnotation/1449168385 => 3_23132388_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/637880534 => 7_87600124_T_C\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1184472900 => 4_70993476_C_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1444705191 => 12_2207029_T_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1448531661 => 16_15995584_A_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1185000052 => 7_99672916_T_C\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1448427972 => 9_84673278_G_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1449718283 => 10_99844450_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1447982818 => 1_39659467_A_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/981237959 => 19_45351661_T_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1450936296 => 16_28608717_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1448522748 => 1_153348279_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1183631554 => 18_63312127_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1444843402 => 16_16031468_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1444704869 => 20_63349752_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1450928486 => 4_3241491_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1451352140 => 21_37917643_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1451678101 => 22_19963748_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1449565422 => 10_94972204_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1183697540 => 12_21176804_A_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1445624605 => 6_160451754_C_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/655386126 => 10_72009832_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1451825220 => 22_19963748_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1447953277 => 6_152103343_A_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1444703380 => 19_15848390_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1449168468 => 6_41237497_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1450931422 => 19_3656654_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1451274045 => 1_97082391_T_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1450930839 => 15_78625057_A_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/655386120 => 10_72010359_T_C\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1444666717 => 10_62045858_T_C\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1183615400 => 4_70993905_A_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1449191564 => 7_117540237_T_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/982030900 => X_123183391_T_C\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1451159780 => 6_29830805_-_ATTTGTTCATGCCT\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1448100089 => 22_38059462_T_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/637880014 => 7_87531302_A_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1448256890 => 2_112840678_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1451121805 => 4_180916588_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1183624421 => 6_77463564_T_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1444665939 => 4_74529595_G_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1450931440 => 19_3634021_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1449003805 => 9_133255670_GGG_GG\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1450815172 => 4_105432212_A_C\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1451398347 => 18_60215554_C_A\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1448262908 => 2_85550510_C_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1447943608 => 7_87509329_A_G\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1449169601 => 14_96204802_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/1448616890 => 6_43302413_C_T\n",
      "https://www.pharmgkb.org/clinicalAnnotation/981238234 => 6_35639794_T_C\n"
     ]
    }
   ],
   "source": [
    "for caid in ca_with_rs['Clinical Annotation ID'].sample(n=50):\n",
    "    print(f'https://www.pharmgkb.org/clinicalAnnotation/{caid} => {get_coordinates_for_clinical_annotation(caid)}')"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7aa5607e",
   "metadata": {},
   "source": [
    "### Option 2\n",
    "\n",
    "* Use `variants.tsv` for chrom & pos, otherwise parse from HGVS\n",
    "* Which HGVS to use is the main issue, also weirdly indirect considering how usually well-defined rsids are\n",
    "* Might generalise better to structural variants but likely not star alleles"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "5a0b1b9f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Variant ID</th>\n",
       "      <th>Variant Name</th>\n",
       "      <th>Gene IDs</th>\n",
       "      <th>Gene Symbols</th>\n",
       "      <th>Location</th>\n",
       "      <th>Variant Annotation count</th>\n",
       "      <th>Clinical Annotation count</th>\n",
       "      <th>Level 1/2 Clinical Annotation count</th>\n",
       "      <th>Guideline Annotation count</th>\n",
       "      <th>Label Annotation count</th>\n",
       "      <th>Synonyms</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>4437</th>\n",
       "      <td>PA166155331</td>\n",
       "      <td>rs45445694</td>\n",
       "      <td>PA134956204,PA359</td>\n",
       "      <td>C18orf56,TYMS</td>\n",
       "      <td>NC_000018.10:657646_657712</td>\n",
       "      <td>87</td>\n",
       "      <td>7</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[8], NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[7], NC_000018.9:g.657646_657673CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NG_028255.1:g.5043_5109=, NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[1], NC_000018.9:g.657646_657712=, NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[4], NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[3], TSER, NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[7], NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[1], NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[3], XM_005258137.1:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.10:g.657657_657712del, NC_000018.10:g.657646_657712=, NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[9], NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[9], NC_000018.10:g.657646_657673CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[4], XM_005258138.1:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[7], 45445694, NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[1], NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[3], NM_001071.2:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[8], NG_028255.1:g.5054_5109del, NG_028255.1:g.5043_5070CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[4], rs45445694, NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[9], NC_000018.9:g.657657_657712del, NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[8], NM_001012716.2:c.*34+169_*34+196CGGGACGGAGGCAGGCCAAGTGGCGCGG[2][3][4][7][8][9]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5839</th>\n",
       "      <td>PA166157516</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>PA109</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>NC_000007.14:117587806</td>\n",
       "      <td>32</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>XM_011515754.1:c.1409G&gt;A, XP_011514056.1:p.Gly470Asp, NG_056131.3:g.761G&gt;A, NG_016465.4:g.127023G&gt;A, NM_000492.3:c.1652G&gt;A, XM_011515753.1:c.1409G&gt;A, NP_000483.3:p.Gly551Asp, NC_000007.13:g.117227860=, NC_000007.14:g.117587806G&gt;A, XM_011515752.1:c.1742G&gt;A, XP_011514053.1:p.Gly581Asp, XP_011514055.1:p.Gly470Asp, 75527207, XM_011515751.1:c.1742G&gt;A, XP_011514054.1:p.Gly581Asp, NC_000007.14:g.117587806=, NG_056131.1:g.130G&gt;A, NG_016465.4:g.127023=, NC_000007.13:g.117227860G&gt;A, rs75527207, NG_056131.1:g.130=, NP_000483.3:p.Gly551=, NG_056131.3:g.761=</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Variant ID Variant Name           Gene IDs   Gene Symbols  \\\n",
       "4437  PA166155331   rs45445694  PA134956204,PA359  C18orf56,TYMS   \n",
       "5839  PA166157516   rs75527207              PA109           CFTR   \n",
       "\n",
       "                        Location  Variant Annotation count  \\\n",
       "4437  NC_000018.10:657646_657712                        87   \n",
       "5839      NC_000007.14:117587806                        32   \n",
       "\n",
       "      Clinical Annotation count  Level 1/2 Clinical Annotation count  \\\n",
       "4437                          7                                    0   \n",
       "5839                          2                                    1   \n",
       "\n",
       "      Guideline Annotation count  Label Annotation count  \\\n",
       "4437                           0                       1   \n",
       "5839                           1                       1   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Synonyms  \n",
       "4437  NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[8], NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[7], NC_000018.9:g.657646_657673CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NG_028255.1:g.5043_5109=, NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[1], NC_000018.9:g.657646_657712=, NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[4], NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[3], TSER, NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[7], NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[1], NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[3], XM_005258137.1:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.10:g.657657_657712del, NC_000018.10:g.657646_657712=, NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[9], NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[9], NC_000018.10:g.657646_657673CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[4], XM_005258138.1:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[7], 45445694, NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[1], NC_000018.9:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[3], NM_001071.2:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[8], NG_028255.1:g.5054_5109del, NG_028255.1:g.5043_5070CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[4], rs45445694, NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[9], NC_000018.9:g.657657_657712del, NG_028255.1:g.5054GGCCTGCCTCCGTCCCGCCGCGCCACTT[8], NM_001012716.2:c.*34+169_*34+196CGGGACGGAGGCAGGCCAAGTGGCGCGG[2][3][4][7][8][9]  \n",
       "5839                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                XM_011515754.1:c.1409G>A, XP_011514056.1:p.Gly470Asp, NG_056131.3:g.761G>A, NG_016465.4:g.127023G>A, NM_000492.3:c.1652G>A, XM_011515753.1:c.1409G>A, NP_000483.3:p.Gly551Asp, NC_000007.13:g.117227860=, NC_000007.14:g.117587806G>A, XM_011515752.1:c.1742G>A, XP_011514053.1:p.Gly581Asp, XP_011514055.1:p.Gly470Asp, 75527207, XM_011515751.1:c.1742G>A, XP_011514054.1:p.Gly581Asp, NC_000007.14:g.117587806=, NG_056131.1:g.130G>A, NG_016465.4:g.127023=, NC_000007.13:g.117227860G>A, rs75527207, NG_056131.1:g.130=, NP_000483.3:p.Gly551=, NG_056131.3:g.761=  "
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "variants[variants['Variant Name'].isin(('rs75527207', 'rs45445694'))]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "b192dddd",
   "metadata": {},
   "outputs": [],
   "source": [
    "from eva_cttv_pipeline.clinvar_xml_io.clinvar_xml_io.hgvs_variant import HgvsVariant, any_sequence_type_regex"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "13879ba1",
   "metadata": {},
   "outputs": [],
   "source": [
    "h = HgvsVariant('NC_000007.14:g.117587806G>A')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "b4ae7353",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(117587806, 117587806, <SequenceType.GENOMIC: 2>, 'NC_000007.14', 'G', 'A')"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "h.start, h.stop, h.sequence_type, h.reference_sequence, h.ref, h.alt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "8ab8cc08",
   "metadata": {},
   "outputs": [],
   "source": [
    "h2 = HgvsVariant('NC_000018.10:g.657657GGCCTGCCTCCGTCCCGCCGCGCCACTT[7]')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "6b65118f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(657657, 657657, 'NC_000018.10', 'GGCCTGCCTCCGTCCCGCCGCGCCACTT')"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "h2.start, h2.stop, h2.reference_sequence, h2.repeat_sequence"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "7fde9904",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<VariantType.SUBSTITUTION: 1>"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "h.variant_type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "7288e954",
   "metadata": {},
   "outputs": [],
   "source": [
    "h2.variant_type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fe2947d0",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
